Ausgabe 6/2012
Inhalt (31 Artikel)
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
Francesco Grossi, Erika Rijavec, Maria Giovanna Dal Bello, Carlotta Defferrari, Annalisa Brianti, Giulia Barletta, Carlo Genova, Carmelina Murolo, Maurizio Cosso, Gabriella Fontanini, Laura Boldrini, Mauro Truini, Paolo Pronzato
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Mei Dong, Zhi-Qiang Ning, Pu-Yuan Xing, Jia-Lian Xu, Hai-Xiang Cao, Gui-Fang Dou, Zhi-Yun Meng, Yuan-Kai Shi, Xian-Ping Lu, Feng-Yi Feng
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent
Elizabeth Rayburn, Wei Wang, Mao Li, Xu Zhang, Hongxia Xu, Haibo Li, Jiang-Jiang Qin, Lee Jia, Joseph Covey, Moses Lee, Ruiwen Zhang
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults
Joseph P. Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum
Fa-Jun Xie, Peng Zhao, Jun-Yan Kou, Wei Hong, Li Fu, Lin Hu, Dan Hong, Dan Su, Yun Gao, Yi-Ping Zhang
Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity
Omar N. Al Safarjalani, Reem Rais, Fardos N. M. Naguib, Mahmoud H. el Kouni
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study
Robert S. Jansen, Hilde Rosing, Pierre W. Wijermans, Ron J. Keizer, Jan H. M. Schellens, Jos H. Beijnen
Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors
E. Calvo, J. B. Vermorken, S. Hiret, J. Rodon, J. Cortes, H. Senellart, J. Van den Brande, J. Dyck, A. Pétain, P. Ferre, J. Bennouna
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
Hajime Asahina, Yosuke Tamura, Hiroshi Nokihara, Noboru Yamamoto, Yoshitaka Seki, Takashi Shibata, Yasushi Goto, Maki Tanioka, Yasuhide Yamada, Andrew Coates, Yi-Lin Chiu, Xiaohui Li, Rajendra Pradhan, Peter J. Ansell, Evelyn M. McKeegan, Mark D. McKee, Dawn M. Carlson, Tomohide Tamura
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Qian Liu, Jessica D. Sun, Jingli Wang, Dharmendra Ahluwalia, Amanda F. Baker, Lee D. Cranmer, Damien Ferraro, Yan Wang, Jian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, Charles P. Hart
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer
Manabu Emi, Jun Hihara, Yoichi Hamai, Yoshiro Aoki, Morihito Okada, Masahiro Kenjo, Yuji Murakami
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
David A. Reardon, Charles A. Conrad, Timothy Cloughesy, Michael D. Prados, Henry S. Friedman, Kenneth D. Aldape, Paul Mischel, Jane Xia, Clifford DiLea, Jerry Huang, William Mietlowski, Margaret Dugan, Wei Chen, W. K. Alfred Yung
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma
Aaron M. Teitelbaum, Jose L. Gallardo, Jessica Bedi, Rajan Giri, Adam R. Benoit, Michael R. Olin, Kate M. Morizio, John R. Ohlfest, Rory P. Remmel, David M. Ferguson
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer
Maiko Asakuma, Michiko Yamamoto, Mayuko Wada, Shinichiro Ryuge, Ken Katono, Masanori Yokoba, Tomoya Fukui, Akira Takakura, Sakiko Otani, Sachiyo Maki, Satoshi Igawa, Tomoko Yanaihara, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Noriyuki Masuda
Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients
Manabu Kume, Hiroyuki Yasui, Yutaka Yoshikawa, Masanori Horinouchi, Kanae Higashiguchi, Yoko Kobayashi, Daisuke Kuroda, Takeshi Hirano, Midori Hirai, Tsutomu Nakamura
The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells
Yuko Takeba, Naoki Matsumoto, Minoru Watanabe, Sachiko Takenoshita-Nakaya, Yuki Ohta, Toshio Kumai, Masayuki Takagi, Satoshi Koizumi, Takeshi Asakura, Takehito Otsubo
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
Federica Grosso, Maurizio D’Incalci, Mirela Cartoafa, Antonio Nieto, Carlos Fernández-Teruel, Vicente Alfaro, Pilar Lardelli, Elena Roy, Javier Gómez, Carmen Kahatt, Arturo Soto-Matos, Ian Judson
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions
Binfeng Xia, Tycho Heimbach, Tsu-han Lin, Handan He, Yanfeng Wang, Eugene Tan
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
M. Acharya, A. Bernard, M. Gonzalez, J. Jiao, R. De Vries, N. Tran
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
M. J. Lamas, G. Duran, E. Balboa, B. Bernardez, S. Candamio, Y. Vidal, A. Mosquera, J. M. Giraldez, R. Lopez, A. Carracedo, F. Barros
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines
Annett Mueller, Erika Bachmann, Monika Linnig, Katrin Khillimberger, Carl Christoph Schimanski, Peter R. Galle, Markus Moehler
An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel
Toshitaka Uchiyama, Hitoshi Kanno, Ken Ishitani, Hisaichi Fujii, Hiroaki Ohta, Hideo Matsui, Naoyuki Kamatani, Kayoko Saito
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI)
Naoya Hida, Hiroaki Okamoto, Yuuki Misumi, Akira Sato, Mari Ishii, Fumihiro Kashizaki, Tsuneo Shimokawa, Teppei Shimizu, Koshiro Watanabe
RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR
Ziwei Liu, Qianying Yuan, Xuenong Zhang, Chaomei Xiong, Pingping Xue, Jinlan Ruan
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Alberto Zaniboni, Enrico Aitini, Sandro Barni, Daris Ferrari, Stefano Cascinu, Vincenzo Catalano, Giuseppe Valmadre, Domenica Ferrara, Enzo Veltri, Claudio Codignola, Roberto Labianca
Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies
Zhen-Hua Wang, Qin-Yan Gao, Jing-Yuan Fang
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B. Perkins, Connie Honeycut, Martha D. Wellons, Tammy Stefan, James W. Jacobberger, Emmanouil Kontopodis, Jan H. Beumer, Merrill J. Egorin, Chiyo K. Imamura, W. Douglas Figg Sr., Judith E. Karp, Omer N. Koc, Brenda W. Cooper, Selina M. Luger, A. Dimitrios Colevas, John D. Roberts, Steven Grant
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model
Sarah R. Mudd, Martin J. Voorbach, David R. Reuter, Paul Tapang, Jonathan A. Hickson, Marion Refici-Buhr, Gerard B. Fox, Daniel H. Albert, Yanping Luo, Mark Day
Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity?
Sandra Rodemeister, Donatus Nohr, Hans K. Biesalski